{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:43:30Z","timestamp":1789965810212,"version":"4.0.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.neuroscience.2019.07.003","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T11:20:05Z","timestamp":1562671205000},"page":"60-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M1 Receptor, and Xanomeline, an Agonist of Muscarinic M1\/M4 Receptor, in Rodents"],"prefix":"10.1016","volume":"414","author":[{"given":"Takao","family":"Mandai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Kurimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohisa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhide","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2019.07.003_bb0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1254\/jphs.93.95","article-title":"Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease","volume":"93","author":"Abe","year":"2003","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/jpet.115.226910","article-title":"Evidence for classical cholinergic toxicity associated with selective activation of M1 muscarinic receptors","volume":"356","author":"Alt","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nn992","article-title":"Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice","volume":"6","author":"Anagnostaras","year":"2003","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0025","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/1531-8249(200012)48:6<868::AID-ANA7>3.0.CO;2-0","article-title":"Delusions associated with elevated muscarinic binding in dementia with Lewy bodies","volume":"48","author":"Ballard","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0030","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0022-3565(24)35328-5","article-title":"The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist","volume":"292","author":"Bartolomeo","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0006-3223(98)00138-3","article-title":"A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives","volume":"44","author":"Benes","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0050","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.0.CO;2-K","article-title":"Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease","volume":"40","author":"Bymaster","year":"1997","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0055","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/npp.2014.2","article-title":"Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100","volume":"39","author":"Byun","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1006\/nlme.2000.3967","article-title":"The genomic action potential","volume":"74","author":"Clayton","year":"2000","journal-title":"Neurobiol Learn Mem"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0065","first-page":"1271","article-title":"What is the function of the claustrum?","volume":"360","author":"Crick","year":"2005","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0070","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0006-3223(00)00918-5","article-title":"Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation","volume":"48","author":"Crook","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0075","first-page":"918","article-title":"Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment","volume":"158","author":"Crook","year":"2001","journal-title":"AJ Psychiatry"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0080","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1021\/acs.jmedchem.6b00544","article-title":"Discovery of the potent and selective M1 PAM-agonist N-[(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)ben zyl]pyridine-2-carboxamide (PF-06767832): evaluation of efficacy and cholinergic side effects","volume":"59","author":"Davoren","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/archpsyc.1973.04200020037004","article-title":"Various enzymes involved with putative neurotransmitters. Regional distribution in the brain of deceased mentally normal, chronic schizophrenics or organic brain syndrome patients","volume":"29","author":"Domino","year":"1973","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0090","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/jnnp.71.4.441","article-title":"Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease","volume":"71","author":"Du","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0095","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/jnp.3.4.383","article-title":"The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia","volume":"3","author":"el-Mallakh","year":"1991","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0100","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0166-2236(91)90117-D","article-title":"Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence","volume":"14","author":"Fibiger","year":"1991","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0105","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.neuroscience.2017.12.020","article-title":"Chronic treatment with fluoxetine or clozapine of socially isolated rats prevents subsector-specific reduction of parvalbumin immunoreactive cells in the hippocampus","volume":"371","author":"Filipovic","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0110","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/npp.2015.189","article-title":"Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model","volume":"41","author":"Ghoshal","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.neuroscience.2015.06.035","article-title":"Age and sex differences in c-Fos expression and serum corticosterone concentration following LPS treatment","volume":"305","author":"Girard-Joyal","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0120","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1021\/acschemneuro.6b00230","article-title":"Prefrontal cortex-mediated impairments in a genetic model of NMDA receptor hypofunction are reversed by the novel M1 PAM VU6004256","volume":"7","author":"Grannan","year":"2016","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0125","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0920-9964(94)90071-X","article-title":"Cortical cholinergic markers in schizophrenia","volume":"12","author":"Haroutunian","year":"1994","journal-title":"Schizophr Res"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0920-9964(99)00178-4","article-title":"Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning task","volume":"43","author":"Hazlett","year":"2000","journal-title":"Schizophr Res"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0135","first-page":"93","article-title":"Milameline: nonselective, partial muscarinic receptor agonist for the treatment of Alzheimer's disease?","volume":"5","author":"Heidrich","year":"1999","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0140","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature13028","article-title":"The hippocampal CA2 region is essential for social memory","volume":"508","author":"Hitti","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0145","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0150","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.lfs.2004.07.029","article-title":"ESP-102, a standardized combined extract of Angelica gigas, Saururus chinensis and Schizandra chinensis, significantly improved scopolamine-induced memory impairment in mice","volume":"76","author":"Kang","year":"2005","journal-title":"Life Sci"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0155","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.celrep.2014.12.014","article-title":"Mapping social behavior-induced brain activation at cellular resolution in the mouse","volume":"10","author":"Kim","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0160","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1124\/jpet.117.243774","article-title":"An approach to discovering novel muscarinic M1 receptor positive allosteric modulators with potent cognitive improvement and minimized gastrointestinal dysfunction","volume":"364","author":"Kurimoto","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0165","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/jpet.115.226712","article-title":"The M1 muscarinic positive allosteric modulator PQCA improves performance on translatable tests of memory and attention in rhesus monkeys","volume":"355","author":"Lange","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0170","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nature05453","article-title":"Genome-wide atlas of gene expression in the adult mouse brain","volume":"445","author":"Lein","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0175","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0024-3205(93)90300-R","article-title":"Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain","volume":"52","author":"Levey","year":"1993","journal-title":"Life Sci"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0180","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrd3628","article-title":"Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy","volume":"11","author":"Millan","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0190","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","article-title":"Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists","volume":"9","author":"Mirza","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0022-510X(99)00289-0","article-title":"Medial temporal atrophy and memory impairment in early stage of Alzheimer's disease: an MRI volumetric and memory assessment study","volume":"173","author":"Mizuno","year":"2000","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0200","first-page":"173","article-title":"Alzheimer's disease severely affects areas of the claustrum connected with the entorhinal cortex","volume":"37","author":"Morys","year":"1996","journal-title":"J Hirnforsch"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0205","first-page":"382","article-title":"Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease","volume":"45","author":"Mosconi","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0210","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.physbeh.2006.09.013","article-title":"Characteristics of object location memory in mice: behavioral and pharmacological studies","volume":"90","author":"Murai","year":"2007","journal-title":"Physiol Behav"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.brainres.2015.12.016","article-title":"Pharmacological properties of a novel and potent gamma-secretase modulator as a therapeutic option for the treatment of Alzheimer's disease","volume":"1633","author":"Murakami","year":"2016","journal-title":"Brain Res"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0220","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ana.10669","article-title":"Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment","volume":"54","author":"Nestor","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0225","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(03)12323-9","article-title":"Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison","volume":"361","author":"Pantelis","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0230","series-title":"The mouse brain in stereotactic coordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0235","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0006-3223(00)01017-9","article-title":"The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex","volume":"49","author":"Perry","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0240","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pscychresns.2011.06.014","article-title":"Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity","volume":"194","author":"Poulin","year":"2011","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0245","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neuroscience.2013.07.010","article-title":"Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2\/3 agonist LY354740","volume":"250","author":"Procaccini","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0250","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2015.03.029","article-title":"The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model","volume":"287","author":"Puri","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0255","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41386-018-0168-8","article-title":"TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects","volume":"44","author":"Sako","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0260","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.schres.2009.07.016","article-title":"Anterior hippocampal and orbitofrontal cortical structural brain abnormalities in association with cognitive deficits in schizophrenia","volume":"114","author":"Schobel","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0265","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0920-9964(99)00138-3","article-title":"Xanomeline, an M(1)\/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice","volume":"42","author":"Shannon","year":"2000","journal-title":"Schizophr Res"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0270","first-page":"1033","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"AJ Psychiatry"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0275","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0022-3565(24)29291-0","article-title":"The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat","volume":"299","author":"Stanhope","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0280","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neuroscience.2018.11.015","article-title":"Brain sub\/region-specific effects of olanzapine on c-Fos expression of chronically socially isolated rats","volume":"396","author":"Stanisavljevic","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0285","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1212\/WNL.54.2.421","article-title":"Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 study group","volume":"54","author":"Thal","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0290","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1517\/17460441.2011.608658","article-title":"Monitoring Gq-coupled receptor response through inositol phosphate quantification with the IP-one assay","volume":"6","author":"Trinquet","year":"2011","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0295","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00213-012-2788-8","article-title":"The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque","volume":"225","author":"Uslaner","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0300","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.117.245894","article-title":"Preclinical to human translational pharmacology of the novel M1 positive allosteric modulator MK-7622","volume":"365","author":"Uslaner","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0305","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00213-014-3813-x","article-title":"Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey","volume":"232","author":"Vardigan","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0310","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/sj.bjp.0702201","article-title":"Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors","volume":"125","author":"Watson","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0315","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7058341","article-title":"Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain","volume":"215","author":"Whitehouse","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0320","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ddr.10085","article-title":"Talsaclidine (WAL 2014 FU), a muscarinic M1 receptor agonist for the treatment of Alzheimer's disease","volume":"56","author":"Wienrich","year":"2002","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0325","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrn.2016.56","article-title":"Over the river, through the woods: cognitive maps in the hippocampus and orbitofrontal cortex","volume":"17","author":"Wikenheiser","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0330","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2008.12.020","article-title":"Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice","volume":"603","author":"Woolley","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neuroscience.2019.07.003_bb0335","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/nn.3813","article-title":"Visualizing an emotional valence map in the limbic forebrain by TAI-FISH","volume":"17","author":"Xiu","year":"2014","journal-title":"Nat Neurosci"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452219304737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452219304737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T15:50:37Z","timestamp":1759679437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452219304737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":67,"alternative-id":["S0306452219304737"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2019.07.003","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M1 Receptor, and Xanomeline, an Agonist of Muscarinic M1\/M4 Receptor, in Rodents","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2019.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 IBRO. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}